Cancer has always been one of the most dangerous disease on our planet. This disease is the number one death of humans worldwide with many different types that are hard to treat. There has not been a way to prevent cancer and the treatments found are either destructive or specific to certain rare types of cancer.
However, this setback has inspired and motivated many team of researchers worldwide to search for any alternatives or solutions. A recent study conducted by George Washington University (GW) Cancer Center showed that a certain enzyme created by the body, USP15, can be manipulated to treat breast and pancreatic cancer.
The study led by Ph.D. holder Huadong Pei, who is also an assistant professor of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences was published in the journal of Nature Communications. He stated, “With this study, we validate the role of USP15 in maintaining genome stability and tumor suppression and inform novel treatments for breast cancer. With consistent research and progress of current studies, we will gain a stronger understanding and a more comprehensive view of USP15 functions in cancer and their role in future treatment strategies.”
The enzyme USP15 was present in a large percentage of humans with breast or pancreatic cancer. This enzyme has showed a direct relation with PARP inhibitors which is a pharmacological inhibitor developed to treat cancer. The enzyme regulates homologous recombination which is the first step towards DNA repair.